Company intelligence / Profile preview

Emercell

Paris, Île-de-France, Franceemercell.com ↗

Ownership: Private
Development stage: Other

Overview

Emercell's lead NK cell therapy (NK-001, also called OT-C001) is entering early clinical trials for relapsed/refractory lymphoma, including diffuse large B-cell lymphoma, after EMA approval of its clinical trial dossier.

Therapeutic areas: Oncology
Modalities: Cell therapyNK cell therapy
Industry: Biotech

Drug pipeline

1 asset

NK-001

IND

Indications: Cancer

Partnerships

Cell-Easy (CDMO/manufacturing scale-up partner)[2]Onward Therapeutics (strategic investment/equity partner)[2]

Beyond the preview

Go deeper on Emercell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emercell.

Explore the full profile